BeOne Medicines
About BeOne Medicines
BeOne Medicines is a biotechnology company dedicated to developing innovative cancer medicines with a global reach. The company focuses on advancing a broad pipeline in hematology and solid tumors, including antibody-drug conjugates and protein degradation strategies, through rigorous science and global partnerships. BeOne emphasizes patient access and collaboration across markets, with operations and offices around the world. It positions itself as a leader in next-generation oncology therapies, aiming to transform cancer treatment worldwide.
Recent News
BeOne Medicines Receives US FDA Accelerated Approval for Beqalzi (Sonrotoclax) to Treat R/R Mantle Cell Lymphoma
Jazz Pharma’s Ziihera Combos Get FDA Priority Review for First‑line HER2‑positive Gastric Cancer
BeOne Medicines Licenses Trispecific Antibody Targeting PD-1, CTLA-4 and VEGF
BeOne Medicines Recognized as "Outstanding Global Oncology Company of the Year" At HKCT Business Awards 2026
FDA Grants Priority Review to BeOne’s TEVIMBRA Combo for HER2+ Gastric Cancer
BeOne’s Next-Gen BCL2 Inhibitor Wins FDA Approval, Taking Aim at Venclexta
BeOne Wins Mantle Cell Lymphoma Approval, Opening New Therapy Class
Regulatory Round-Up: A Month of Key FDA Approvals for Cancer Drugs
Top Biotech Deals in April 2026
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
FDA Hands BeOne, Taiho Approvals for Blood Cancers